ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2814

Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs

Fenglong Xie1, Lang Chen1, Emily Levitan2, Paul M. Muntner2 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, DMARDs, methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T088 ACR Abstract: RA–DX, Manifestations, & Outcomes IV: CV Co-Morbidities (2814–2819)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to biologic disease-modifying antirheumatic drugs (bDMARDS). Effect of concomitant MTX use on CVD risk among RA patients initiating bDMARDS remains unknown.

Methods: A retrospective cohort study was conducted using 2006-2015 Medicare claims data for RA patients. Follow up started at initiation (index date) and ended at earliest of 1) end of exposure of the specific bDMARDS agent (days of supply + 90 day extension), 2) switched to other bDMARDS or tofacitinib, 3) CVD event, 4) death date, 5) loss of Medicare coverage, 6) end of study (September 30, 2015). MTX use was defined as 1) concomitant MTX use, with prescription for MTX within 120 days after index date and 2) time varying MTX, defined as prescription date to prescription date plus days of supply without extension. For sensitivity analysis, a 90-day extension was added to days of supply. The primary outcome was composite of incident MI, incident stroke and fatal CVD. Fatal CVD were identified by a claims based algorithm with PPV ≥80%. Incidence rates (IR) and 95% confidence intervals (CI) were calculated using Poisson regression. Overall association between MTX use and risk of CVD were assessed using Cox regression. Given that the interactions between MTX and background bDMARDs was significant, we performed contrast (MTX Yes vs. No) to examine the association between MTX and risk for CVD for each underlying bDMARDS in one model. A subgroup analysis limited the cohort to RA patients with previous exposure to MTX was conducted to ensure consistency of findings.

Results: A total of 88,255 DMARDS initiations (64,218 patients) were included in this study. The average age at initiation was 64.6 (12.3) years, 84.0% were female, 68.2% were non-Hispanic white. The crude IRs for CVD were 13.1 (95%CI: 12.2-14.0) and 18.7 (95%CI: 17.6-19.9) events per 1,000 person years (PY) for RA patients with and without concomitant MTX respectively. The crude IRs for CVD were 12.1 (95%CI: 11.1-13.2) and 17.9 (95%CI: 16.9-18.8) events per 1,000 PY for RA patients with and without time varying MTX respectively. IRs for individual bDMARDS are shown in figure. P-value for interaction between concomitant MTX and background bDMARDS was 0.0189 and p-value for interaction between time varying MTX and background bDMARDS was 0.0030. The contrast HRs for concomitant MTX ranged from 0.61 (0.37, 1.01) for golimumab initiators to 0.97 (0.74, 1.26) for adalimumab initiators (Figure). The contrast HRs for time varying MTX ranged from 0.58 (0.35, 0.96) for certolizumab initiators to 0.90 (0.68, 1.18) for adalimumab initiators. Results were robust in sensitivity and subgroup analyses.

Conclusion: Our observational study suggests an overall 23% reduction of CVD risk associated with concomitant MTX use. The effect sizes vary among background bDMARDS.


Disclosure: F. Xie, None; L. Chen, None; E. Levitan, Amgen Inc., 2, 5,Novartis, 5; P. M. Muntner, None; J. R. Curtis, Amgen Inc., 2, 5,AbbVie Inc., 2, 5,BMS, 2, 5,Corrona, LLC, 2, 5,Janssen, 2, 5,Eli Lilly, 2, 5,Myriad, 2, 5,Pfizer, Inc., 2, 5,Roche/Genentech, 2, 5,Radius, 2, 5,UCB, Inc., 2, 5.

To cite this abstract in AMA style:

Xie F, Chen L, Levitan E, Muntner PM, Curtis JR. Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/methotrexate-use-and-the-risk-for-cardiovascular-disease-among-rheumatoid-patients-initiating-biologic-disease-modifying-anti-rheumatic-drugs/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-use-and-the-risk-for-cardiovascular-disease-among-rheumatoid-patients-initiating-biologic-disease-modifying-anti-rheumatic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology